NCT03826719View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 17, 2014

Primary Completion Date

March 28, 2014

Study Completion Date

March 28, 2014

Conditions
Influenza
Interventions
BIOLOGICAL

NBP607QIV

Purified inactivated influenza virus surface antigens of four strains(quadrivalent)

BIOLOGICAL

Agrippal

Influenza virus surface antigens of three strains(trivalent)

All Listed Sponsors
lead

SK Chemicals Co., Ltd.

INDUSTRY

NCT03826719 - Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter